Every pharmaceutical company collects enormous amounts of data. Electronic health records, claims databases, patient support programs, Medical Affairs activities, market research, and real-world evidence all generate valuable insights every day. Yet despite this wealth of information, many organizations still struggle to answer fundamental questions: Why are patients diagnosed too late? Where do they discontinue treatment? Which barriers prevent timely access to therapy? And which interventions truly improve patient outcomes?

The problem isn’t a lack of data—it’s the inability to connect fragmented information into a meaningful patient journey analysis. When clinical, operational, and patient-generated data remain isolated, companies see only individual touchpoints instead of the complete patient experience. This often leads to missed care gaps, inefficient Medical Affairs strategies, weaker stakeholder engagement, and patient support initiatives that fail to address real-world needs. The longer these blind spots remain, the greater the impact on patient outcomes, resource allocation, and commercial success.

Beyond affecting patient outcomes, fragmented data also creates significant business challenges. Pharmaceutical companies may invest substantial resources in Medical Affairs initiatives, patient support programs, or market access strategies without fully understanding where patients encounter barriers or why interventions fail to achieve the expected impact. As a result, valuable opportunities to improve patient care and optimize strategic investments can be missed.

The good news is that these challenges are preventable. A robust patient journey analysis combines multiple evidence sources to create a comprehensive view of the patient’s experience—from the first symptoms through diagnosis, treatment, follow-up, and long-term disease management. Understanding what data sources to use for end-to-end patient journey mapping is the first step, but transforming those data into actionable, patient-centric strategies is what ultimately drives measurable improvements. At Billev Pharma East, we help pharmaceutical companies bridge this gap by combining Medical Affairs expertise, patient insights, and evidence-based analysis to identify care gaps, strengthen patient-centric strategies, and improve outcomes across the entire patient journey.

Key Takeaways

• Patient journey analysis requires multiple complementary data sources.
• Clinical data alone cannot provide a complete understanding of the patient journey.Patient voice is essential for identifying unmet needs.
• Combining qualitative and quantitative evidence improves decision-making.
• Billev Pharma East helps pharmaceutical companies transform fragmented data into actionable patient-centric strategies.

What does effective patient journey analysis require?

Successful patient journey analysis begins long before data collection. It starts with a clear understanding of the business challenge, the patient population, and the outcomes pharmaceutical companies want to improve. Without a structured methodology, organizations often collect vast amounts of information that never translate into meaningful action.

An effective analysis requires an end-to-end perspective that follows patients from the first symptoms through diagnosis, treatment initiation, long-term disease management, and follow-up. Every stage introduces different barriers that influence adherence, treatment decisions, patient satisfaction, and ultimately clinical outcomes.

To achieve meaningful results, pharmaceutical companies should:

• define clear objectives before collecting data;
• identify every critical patient touchpoint;
• combine quantitative and qualitative evidence;
• integrate the patient voice throughout the analysis;
• involve Medical Affairs, market access, commercial, and external stakeholders.

While these principles may appear straightforward, implementing them consistently across multiple healthcare systems and stakeholders is often one of the greatest challenges. Research shows that successful patient journey mapping projects typically combine qualitative and quantitative approaches to identify care gaps, understand patient experiences, and support healthcare service improvement.

European Medicines Agency (EMA) guidance also highlights that high-quality real-world evidence depends on selecting data sources that are fit for the research question rather than relying on a single dataset. Combining electronic health records, disease registries, claims data, patient-reported outcomes, prescribing information, and other healthcare data creates a more complete understanding of the patient journey.

Ultimately, effective patient journey analysis is about transforming fragmented healthcare information into evidence-based decisions that improve patient outcomes while supporting strategic planning across the pharmaceutical product lifecycle.

Why most pharmaceutical companies need expert support

Although many pharmaceutical companies recognize the importance of patient-centricity, building a truly comprehensive patient journey analysis is rarely straightforward.

Healthcare data are often scattered across multiple systems, departments, and external stakeholders. Clinical data explain disease progression, reimbursement claims reveal healthcare utilization, while patient interviews uncover barriers that structured databases cannot capture. When these sources remain disconnected, organizations risk overlooking critical care gaps and making decisions based on incomplete evidence.

For example, Electronic Health Records may indicate when treatment was initiated, while claims data show whether therapy continued. However, neither source explains why patients discontinued treatment. Those answers often emerge only when quantitative evidence is complemented by patient interviews, advisory boards, or patient-reported outcomes. Bringing these perspectives together requires both methodological expertise and a deep understanding of healthcare systems.

Another common challenge is interpreting the data. Large datasets alone do not explain why patients delay diagnosis, discontinue therapy, or struggle to navigate complex healthcare pathways. Answering these questions requires medical expertise, an understanding of healthcare systems, and the ability to integrate scientific evidence with real-world patient experiences.

For this reason, many pharmaceutical organizations choose to work with specialized partners who understand both Medical Affairs and patient-centric strategy. External expertise accelerates evidence generation, strengthens stakeholder alignment, and helps organizations identify opportunities that may otherwise remain hidden.

Rather than simply collecting more data, the goal is to generate insights that lead to measurable improvements in access, adherence, education, and patient outcomes.

How Billev Pharma East delivers actionable patient journey analysis

At Billev Pharma East, we believe that successful patient journey analysis is not about collecting more data—it’s about understanding what the data reveal about the real experiences of patients and translating those insights into strategic action. Many pharmaceutical companies already have access to clinical data, market research, patient support program information, and real-world evidence, yet they often struggle to connect these sources into a coherent picture that supports better decision-making.

Our role is to bridge that gap. We work closely with pharmaceutical companies to develop a comprehensive understanding of the entire patient journey, from the first symptoms and diagnosis to treatment initiation, long-term disease management, and follow-up. By analysing every stage of the journey, we identify where patients encounter barriers, where care gaps exist, and where targeted interventions can create the greatest impact. This structured approach helps organizations move beyond assumptions and base their strategies on evidence and real patient needs rather than fragmented information.

What makes our approach different is the combination of scientific expertise and practical implementation. Our multidisciplinary team integrates Medical Affairs knowledge, clinical research experience, regulatory understanding, pharmacovigilance, quality management, and health economics to ensure that every recommendation is both patient-centric and operationally feasible. Instead of delivering a static patient journey map, we provide actionable insights that strengthen stakeholder engagement, improve patient education, support evidence generation, and help organizations design initiatives that reduce delays, improve adherence, and enhance patient outcomes across the entire care pathway.

Rather than applying a one-size-fits-all methodology, we tailor every patient journey analysis to the specific therapeutic area, business objective, and healthcare environment. Whether the goal is to improve diagnosis pathways, strengthen patient support, identify unmet needs, or optimize Medical Affairs activities, our analyses are designed to generate insights that can be translated into practical actions.

Ultimately, our goal is to help pharmaceutical companies transform patient journey analysis into measurable value. By combining patient journey understanding, care gap identification, integrated care alignment, and patient voice integration, we enable our clients to build patient-centric strategies that improve healthcare outcomes while supporting long-term business success. This approach reflects how Billev Pharma East positions its patient journey services: moving from fragmented insights to coordinated, evidence-based actions that create sustainable impact across the healthcare ecosystem.

Every patient journey analysis project begins with different questions. Our role is to help pharmaceutical companies identify the right data sources, interpret complex evidence, and translate findings into patient-centric strategies that deliver measurable value.

What data sources to use for end-to-end patient journey mapping

A comprehensive patient journey analysis depends on the quality, diversity, and integration of the data used. No single dataset can capture the complexity of a patient’s experience from symptom onset to long-term disease management. Instead, pharmaceutical companies need to combine multiple complementary data sources to understand not only what happens throughout the patient journey, but also why it happens.

Data source	What it reveals
Electronic Health Records (EHRs)	Diagnosis, disease progression, clinical outcomes
Claims data	Healthcare utilization, treatment persistence, reimbursement patterns
Disease registries	Long-term outcomes, epidemiology, disease progression
Patient interviews	Experiences, unmet needs, emotional and practical barriers
Patient-reported outcomes (PROs)	Quality of life, treatment burden, symptom management
Digital health tools	Behaviour, adherence patterns, remote monitoring insights
Market research	Stakeholder perceptions, decision drivers, healthcare trends

Each data source contributes a unique perspective, but meaningful patient journey analysis requires integrating these complementary datasets to answer specific clinical and business questions rather than analysing them in isolation. The European Medicines Agency (EMA) also emphasizes that data sources should be selected according to the research question and combined to generate reliable real-world evidence.

However, data alone do not provide meaningful insights. Organizations must first determine which business or medical questions they want to answer. For example, are they trying to identify diagnostic delays, understand treatment discontinuation, improve adherence, or evaluate access to innovative therapies? The answer determines which combination of data sources is most appropriate.

For pharmaceutical companies, the challenge is therefore not simply deciding what data sources to use for end-to-end patient journey mapping, but integrating clinical evidence with patient experiences and healthcare system data to create a complete, patient-centric view. When these data sources are analysed together, they reveal care gaps, unmet needs, and opportunities to improve both patient outcomes and strategic decision-making throughout the product lifecycle.

How do you combine multiple data sources into actionable patient journey insights?

Collecting healthcare data is only the first step. The real value of patient journey analysis lies in integrating multiple data sources to create a complete picture of the patient experience. Each dataset provides a different perspective, but none is sufficient on its own. Electronic Health Records (EHRs) explain the clinical pathway, claims data reveal healthcare utilization and reimbursement patterns, disease registries provide long-term outcome information, while patient-reported outcomes and interviews uncover experiences, preferences, and barriers that structured clinical data cannot capture. The European Medicines Agency (EMA) emphasizes that real-world evidence is most valuable when data sources are selected according to the research question and combined using robust methodological approaches.

Consider an oncology patient journey. Electronic Health Records may identify delays between symptom onset and diagnosis, claims data can reveal treatment persistence, while patient interviews explain why some individuals discontinue therapy despite clinical recommendations. Combining these perspectives enables pharmaceutical companies to identify root causes rather than isolated events.

The integration process should always begin with a clearly defined objective. Pharmaceutical companies must first determine what they want to understand, whether it is delayed diagnosis, poor treatment adherence, inequitable access to innovative therapies, or unmet patient needs. Once the objective is established, the appropriate combination of data sources can be selected to answer that specific question.

However, successful integration requires more than technical expertise. Different datasets often use different coding systems, formats, and levels of completeness, making interpretation challenging without clinical and Medical Affairs expertise. This is why patient journey analysis should combine quantitative evidence with qualitative patient insights. Together, these sources provide a holistic understanding of the patient journey and enable pharmaceutical companies to identify care gaps, prioritize interventions, and develop patient-centric strategies that improve both healthcare outcomes and business performance.

What mistakes should pharmaceutical companies avoid during patient journey analysis?

Many patient journey analysis projects fail not because organizations lack data, but because they rely on incomplete evidence or begin the analysis without a clear strategic objective. One of the most common mistakes is focusing on a single data source, such as electronic health records or claims data, and assuming it represents the entire patient experience. In reality, every dataset has limitations and must be interpreted alongside complementary sources to provide meaningful insights. EMA guidance also highlights the importance of selecting fit-for-purpose data sources and ensuring data quality before generating real-world evidence.

Common mistakes

• analysing only one dataset;
• ignoring patient voice;
• defining objectives too broadly;
• collecting data without an implementation plan;
• failing to engage cross-functional stakeholders.

Another frequent challenge is overlooking the patient perspective. Clinical outcomes explain what happened during treatment, but they rarely reveal why patients delay diagnosis, discontinue therapy, or struggle to adhere to treatment plans. Without incorporating patient interviews, patient-reported outcomes, or other forms of patient voice, organizations risk designing initiatives that fail to address real-world needs.

Finally, many companies generate extensive analyses but never translate the findings into practical action. The purpose of patient journey analysis is not to produce another report—it is to identify opportunities that improve patient outcomes, strengthen Medical Affairs strategies, optimize stakeholder engagement, and support evidence-based decision-making. Organizations that successfully transform insights into targeted interventions are far more likely to improve access, adherence, and the overall patient experience throughout the healthcare journey.

Turning patient journey analysis into better patient outcomes

Successful patient journey analysis is not defined by the amount of data an organization collects, but by its ability to transform diverse healthcare data into meaningful, patient-centric action. As this article has shown, answering the question “what data sources to use for end-to-end patient journey mapping” requires more than selecting individual datasets. It requires combining clinical information, real-world evidence, healthcare utilization data, patient-reported outcomes, and the patient voice to create a comprehensive understanding of the entire patient experience. European Medicines Agency (EMA) guidance also emphasizes that robust real-world evidence depends on selecting fit-for-purpose data sources and integrating them to answer clearly defined research questions.

However, data alone do not improve patient outcomes. The real value lies in identifying care gaps, understanding the factors that influence diagnosis, treatment, adherence, and long-term disease management, and translating those insights into evidence-based strategies that deliver measurable improvements. This is where many pharmaceutical companies face their greatest challenge—not because they lack information, but because connecting fragmented data into actionable insights requires specialized expertise across Medical Affairs, patient-centric strategy, and healthcare systems.

At Billev Pharma East, we help pharmaceutical companies move beyond fragmented datasets and isolated analyses. By combining scientific expertise with patient journey understanding, care gap identification, integrated care alignment, and patient voice integration, we support organizations in developing patient journey analysis that drives informed decision-making and meaningful improvements across the entire patient journey. Our patient-centric approach enables companies to strengthen Medical Affairs strategies, improve stakeholder collaboration, reduce delays and patient drop-offs, and ultimately deliver better outcomes for both patients and healthcare systems.

Organizations that invest in patient journey analysis today are better positioned to anticipate changing patient needs, strengthen evidence generation, and develop more patient-centric healthcare strategies. The greatest value does not come from collecting more information—it comes from connecting the right data, asking the right questions, and transforming evidence into action.

Whether your objective is to identify care gaps, improve patient adherence, optimize Medical Affairs activities, or better understand real-world treatment pathways, successful patient journey analysis starts with asking the right questions and using the right evidence. If your organization is looking to transform healthcare data into actionable patient insights, Billev Pharma East is ready to help you build evidence-based, patient-centric strategies that create lasting value across every stage of the patient journey.

Frequently asked questions

Sources: 1 – European Medicines Agency. (2025). Real-world evidence, 2 – European Medicines Agency. (2024). Guide on real-world evidence provided by EMA: Support for regulatory decision-making (EMA/152628/2024), 3 – European Medicines Agency. (2025). Data Analysis and Real World Interrogation Network (DARWIN EU).